Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
With the global burden of respiratory diseases, rapid identification of the best therapeutic measures to combat these diseases is essential. Animal models and 2D cell culture models do not replicate the findings observed in vivo. To gain deeper insight into lung pathology and physiology, 3D and advanced lung-on-a-chip models have been developed recently. Lung-on-a-chip models more accurately simulate the lung's microenvironment and functions in vivo, resulting in more-accurate assessments of drug safety and effectiveness. This review discusses the transition from 2D to 3D models and the recent advances in lung-on-a-chip platforms, their implementation and the numerous challenges faced. Finally, a general overview of this platform and its potential applications in respiratory disease research and drug discovery is highlighted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2022.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Models of Surfactant Replacement Therapy in Neonatal Lungs.
J Biomech Eng
September 2025
Department of Biomedical Engineering, The University of Akron, 244 Sumner Street Akron, OH 44325.
The lungs play a critical role in gas exchange and overall respiratory functions, relying on a delicate balance of pulmonary mechanics and surfactant homeostasis. Surfactant replacement therapy (SRT) is a life-saving intervention for conditions such as neonatal respiratory distress syndrome (NRDS), where surfactant deficiency impairs alveolar stability and normal gas exchange. To improve treatment strategies of lung disorders such as NRDS, researchers have developed a variety of computational, benchtop, and animal models to investigate surfactant transport and drug delivery in the lungs.
View Article and Find Full Text PDFAnimal models for connective tissue disease-associated interstitial lung disease: Current status and future directions.
Autoimmun Rev
August 2025
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610093, China; West China Lecheng Hospital, Sichuan University, Boao, Hainan 571435, China. Electroni
Interstitial lung disease (ILD) significantly contributes to connective tissue disease (CTD) mortality. Although guidelines for managing CTD-associated ILD (CTD-ILD) exist, many patients respond poorly to treatment owing to two key factors: (1) incomplete understanding of subtype-specific pathogenic mechanisms, and (2) reliance on therapies adapted from systemic sclerosis or nonpulmonary rheumatic diseases, which fail to address the unique pathophysiology of distinct CTD-ILD subtypes. This hinders personalized treatment and underscores the need for robust preclinical models that accurately replicate disease-specific mechanisms.
View Article and Find Full Text PDFIn vitro biomimetic models for respiratory diseases: progress in lung organoids and lung-on-a-chip.
Stem Cell Res Ther
July 2025
Institute of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma & War Injuries PLA, No. 51 Fucheng Road, Beijing, 100048, People's Republic of China.
Respiratory diseases pose a growing global public health challenge due to their rising incidence and mortality. Conventional cellular and animal models fall short in replicating the complex three-dimensional (3D) microenvironments of the lung and are limited by species differences, restricting their clinical relevance. Emerging technologies, such as lung organoids (LOs) and lung-on-a-chip (LOC), combine stem cell differentiation, microfluidic systems, and biomechanical cues to create advanced in vitro models that address these limitations.
View Article and Find Full Text PDFRecent Applications of Lung Organoid and Lung-on-a-Chip Technologies for Evaluating the Toxicity of Fine Particulate Matter.
Int J Stem Cells
July 2025
Department of Internal Medicine, College of Medicine, Kangwon National University, Chuncheon, Korea.
There is mounting epidemiologic and experimental evidence of the harmful effects of exposure to fine particulate matter (PM2.5) on human lung health. However, the current utilization of two-dimensional (2D) cell culture and animal models falls short in accurately recapitulating the complexity, functions, and development of the human lung.
View Article and Find Full Text PDFRespiratory microphysiological system in respiratory research: recent advances and future prospects.
Respir Res
July 2025
Department of Testing and Diagnosis Technology Research, Guangzhou National Laboratory, Guangzhou, 510005, China.
Respiratory diseases encompass a broad range of conditions that affect the airways, alveolus, and other structures involved in breathing. With respiratory viruses emerging and spreading rapidly, and factors like air pollution, smoking, occupational hazards, and genetics as major risk contributors, respiratory diseases have emerged as a primary cause of illness and mortality around the globe. The development of in vitro respiratory microphysiological systems (MPS), like lung organoids and lung-on-a-chip models, is essential for preventing and treating these diseases effectively.
View Article and Find Full Text PDF